Atlas Venture Life Science Advisors, LLC Biotechnology

Atlas Venture Life Science Advisors, LLC

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
DYN Dyne Therapeutics, Inc.	$1.54B	$288 Million 35.54% of portfolio	8,020,136	Q1 2024 Reduced 18.87%
KYMR Kymera Therapeutics, Inc.	$2.46B	$232 Million 28.59% of portfolio	4,896,462	Q3 2024 Reduced 8.48%
THRD Third Harmonic Bio, Inc.	$503M	$148 Million 18.24% of portfolio	10,907,859	Q3 2022 New
DAWN Day One Biopharmaceuticals, Inc.	$1.01B	$89.6 Million 11.05% of portfolio	6,430,257	Q1 2024 Reduced 15.48%
GBIO Generation Bio Co.	$80.8M	$20.5 Million 2.52% of portfolio	8,279,484	Q1 2023 Added 0.01%
VIGL Vigil Neuroscience, Inc.	$85.7M	$19.8 Million 2.45% of portfolio	5,836,874	Q1 2022 New
IKNA Ikena Oncology, Inc.	$62.7M	$8.68 Million 1.07% of portfolio	5,018,178	Q4 2021 New
AVTE Aerovate Therapeutics, Inc.	$65M	$3.76 Million 0.46% of portfolio	1,799,232	Q2 2024 Reduced 11.77%
SPRO Spero Therapeutics, Inc.	$41.7M	$539,000 0.07% of portfolio	402,885	Q3 2024 Reduced 24.74%

Get notified when there are updates to the investment portfolio of Atlas Venture Life Science Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Venture Life Science Advisors, LLC with notifications on news.